ArticlePharmaceutics2022
Mono-Rhamnolipid Biosurfactants Synthesized by
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Biosurfactant-Based Interventions for Improving Lung Function and Controlling Inflammation.Pharmaceutical research · 2026Review
- Sugar Esters of Fatty Acids: Chemo-Enzymatic Synthesis and Biological Activity.Molecules (Basel, Switzerland) · 2025Review
- The Application of Glycolipid-Type Microbial Biosurfactants as Active Pharmaceutical Ingredients for the Treatment and Prevention of Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Oncolytic bacteria: A revolutionary approach to cancer therapy.Open life sciences · 2025Review
- Article
- Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.Discover oncology · 2024Review
- Bacterial products initiation of alpha-synuclein pathology: an in vitro study.Scientific reports · 2024Article
- Production and characterization of rhamnolipids by Pseudomonas aeruginosa isolated in the Amazon region, and potential antiviral, antitumor, and antimicrobial activity.Scientific reports · 2024Article
- Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Sustainable biosurfactant production from secondary feedstock-recent advances, process optimization and perspectives.Frontiers in chemistry · 2024Review
- An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.Biology · 2023Review
- Glycolipid Biosurfactants in Skincare Applications: Challenges and Recommendations for Future Exploitation.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Over the past 15 years, glycolipid-type biosurfactant compounds have been postulated as novel, naturally synthesized anticancer agents. This study utilized a recombinant strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.